212 related articles for article (PubMed ID: 12056704)
1. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Venturini M; Del Mastro L; Garrone O; Angiolini C; Merlano M; Bergaglio M; Tolino G; Lambiase A; Baldini A; Canavese G; Rosso R
Ann Oncol; 2002 Apr; 13(4):546-52. PubMed ID: 12056704
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Venturini M; Durando A; Garrone O; Colozza MA; Contu A; Stevani I; Genta F; Bighin C; Lambiase A; Del Mastro L
Cancer; 2003 Mar; 97(5):1174-80. PubMed ID: 12599222
[TBL] [Abstract][Full Text] [Related]
3. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
[TBL] [Abstract][Full Text] [Related]
4. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Michalaki V; Gennatas S; Gennatas K
Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Waters SH; Gillibrand A; Berry H; Kumar S; Velikova G; Dodwell DJ; Perren TJ
Cancer Chemother Pharmacol; 2009 Jul; 64(2):407-12. PubMed ID: 19455333
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Mavroudis D; Papakotoulas P; Ardavanis A; Syrigos K; Kakolyris S; Ziras N; Kouroussis C; Malamos N; Polyzos A; Christophyllakis C; Kentepozidis N; Georgoulias V;
Ann Oncol; 2010 Jan; 21(1):48-54. PubMed ID: 19906761
[TBL] [Abstract][Full Text] [Related]
7. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Venturini M; Michelotti A; Papaldo P; Del Mastro L; Bergaglio M; Lionetto R; Lunardi G; Sguotti C; Frevola L; Donati S; Rosso R; Cognetti F
Ann Oncol; 2001 Aug; 12(8):1097-106. PubMed ID: 11583191
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
9. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Nieto Y; Aramendía JM; Espinós J; De la Cruz S; Fernández-Hidalgo O; Santisteban M; Arbea L; Aristu J; Martínez-Monge R; Moreno M; Pina L; Sola J; Zornoza G; Regueira FM
Cancer Chemother Pharmacol; 2010 Feb; 65(3):457-65. PubMed ID: 19526361
[TBL] [Abstract][Full Text] [Related]
10. [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Tagaya N; Nakagawa A; Mori S; Hamada K; Suzuki N; Kubota K
Gan To Kagaku Ryoho; 2006 Jan; 33(1):39-42. PubMed ID: 16410696
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
[TBL] [Abstract][Full Text] [Related]
12. Treatment for anthracycline-pretreated metastatic breast cancer.
O'Shaughnessy J; Twelves C; Aapro M
Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J
Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952
[TBL] [Abstract][Full Text] [Related]
16. [Clinical paired study of comparing docetaxel plus capecitabine versus docetaxel plus epirubicin as first-line treatment in women with HER-2 negative advanced breast cancer].
Yang B; Yang JL; Shi WW; Liu H; Zhu YY; Fang P; Ji TF
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1397-400. PubMed ID: 24025504
[TBL] [Abstract][Full Text] [Related]
17. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Viens P; Roché H; Kerbrat P; Fumoleau P; Guastalla JP; Delozier T
Am J Clin Oncol; 2001 Aug; 24(4):328-35. PubMed ID: 11474255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]